Healthcare
China Shineway Pharmaceutical Group Limited(CSWYF)
Live Price
Offline$1.00
+0.00% today
1Y Change
+0.00%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $6.05B
- Revenue Growth
- -17.0%
- EPS Growth
- +13.5%
- Dividend Yield
- 6.6%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
China Shineway Pharmaceutical Group Limited (CSWYF) is a Healthcare stock with a market cap of $6.05B and listed on OTC. The stock last traded around $1.00 and up 0.0% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -17.0%, EPS growth of +13.5%, a dividend yield of 6.6%. What stands out right now is revenue -17.0%, EPS +13.5%, free cash flow +18.4% with operating margin 21.8% and ROIC 5.9%. The dividend matters to the case here, with a current yield around 6.6%. Valuation is more restrained than many high-expectation growth names at P/E 6.4 and price/sales 1.9. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines CSWYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-17.0% vs +7.6% peer median
Operating Margin
Above sector median
+21.8% vs +19.4% peer median
P/E
Below sector median
6.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 26, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -17.0% and EPS is at +13.5%, with operating margin around 21.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 6.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 26, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Sep 1, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Mar 26, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
CSWYF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CSWYF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CSWYF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CSWYF and SPY.
Company Overview
China Shineway Pharmaceutical Group Limited
OTC
China Shineway Pharmaceutical Group Limited operates as a pharmaceutical entity specializing in the research, development, production, and distribution of traditional Chinese medicines. The core function of this company is to develop and supply a diverse array of products, including injections, granules, and oral solutions, which are rooted in time-tested traditional Chinese medicine practices. These products are widely used in healthcare sectors for their therapeutic properties and are instrumental in treating common ailments through alternative medicine approaches. China Shineway's operations significantly impact the healthcare and pharmaceutical industries, alongside contributing to the commercialization and international dissemination of traditional Chinese medicine. With its prominent presence in the Chinese market, the company's role is critical in synthesizing modern production techniques with ancient medicinal knowledge, thereby offering comprehensive healthcare solutions and expanding the reach of traditional medicine globally.
- Employees
- 2.8k
- Street Address
- No. 168, Shiluan Street, Luan Cheng District
- Mailing
- Shijiazhuang, 051430
- Region
- Shijiazhuang, China
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 6.4
- EV/EBITDA
- โ
- Price/Sales
- 1.9
- Price/Book
- 0.8
Growth
- Revenue
- -17.0%
- EPS
- +13.5%
- Free Cash Flow
- +18.4%
Profitability
- Gross Margin
- 72.3%
- Operating Margin
- 21.8%
- Net Margin
- 30.4%
- ROE
- 11.9%
- ROIC
- 5.9%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 3.71
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.